ANO7 Antibody

What is ANO7 and what is its biological significance?

ANO7 (Anoctamin 7), also known as NGEP, PCANAP5, and TMEM16G, belongs to the anoctamin family of proteins. It functions as a calcium-activated chloride ion channel and is specifically expressed in prostate epithelial cells . The protein has a calculated molecular weight of 105 kDa and an observed molecular weight of approximately 106 kDa in experimental conditions . ANO7 is believed to play a role in cell-cell interactions, though its exact biological function remains under investigation . Its highly tissue-specific expression pattern makes it a particularly interesting target for prostate cancer research and potential therapeutic applications.

What detection methods are available for ANO7 antibodies?

ANO7 can be detected using several established techniques:

Immunohistochemistry protocols typically involve deparaffinization of tissue sections, heat-induced antigen retrieval in pH 7.8 Tris-EDTA buffer at 121°C for 5 minutes, followed by primary antibody incubation at 37°C for 60 minutes . Visualization is commonly achieved using detection kits such as EnVision Kit according to manufacturer's specifications . For optimal results, researchers should titrate the antibody concentration for their specific experimental system .

How is ANO7 expression evaluated in tissue samples?

Evaluating ANO7 expression in tissue samples involves both qualitative and quantitative assessments. In immunohistochemistry applications, ANO7 shows cytoplasmic staining, and expression evaluation typically includes:

• Staining intensity scoring on a scale of 0 (negative), 1+ (weak), 2+ (moderate), to 3+ (strong)

• Percentage of positively stained cells

• Combined scoring system that incorporates both parameters

For example, a standardized scoring system might classify samples as:

• Negative: Complete absence of staining (intensity 0)

• Weak: 1+ staining in ≤70% of cells or 2+ staining in ≤30% of cells

• Moderate: 1+ staining in >70% of cells or 2+ staining in >30% but ≤70% of cells or 3+ staining in ≤30% of cells

• Strong: 2+ staining in >70% of cells or 3+ staining in >30% of cells

This detailed scoring approach enables meaningful comparison across studies and correlation with clinical parameters.

How does ANO7 expression pattern change during prostate cancer progression?

• Normal tissue: Strong, consistent expression

• Low-grade prostate cancer: Variable expression levels

• Advanced prostate cancer: Significantly reduced expression

Large-scale immunohistochemical studies have demonstrated that ANO7 staining in prostate cancer specimens (n=13,594) can be categorized as strong in 34.4%, moderate in 48.7%, weak in 9.3%, and negative in 7.6% of cases . Reduced ANO7 expression is significantly associated with adverse tumor features including high Gleason grade, lymph node metastasis, advanced tumor stage, high Ki67 labeling index, positive surgical margins, and early biochemical recurrence (p<0.0001 for each parameter) . This consistent pattern supports the value of ANO7 as a prognostic marker.

What is the significance of ANO7 genetic variants in prostate cancer research?

Several ANO7 genetic variants have been identified with significant associations to prostate cancer risk and aggressiveness:

The variant rs77559646 functions as an expression quantitative trait locus (eQTL) for ANO7, affecting mRNA expression levels . Understanding these genetic variants is crucial for developing comprehensive genetic testing panels for prostate cancer risk assessment and personalized treatment approaches.

What is the significance of ANO7 mRNA nuclear enrichment?

One of the most surprising discoveries in ANO7 research is the significant nuclear enrichment of its mRNA. Fluorescent in situ hybridization studies have demonstrated that ANO7 mRNA is predominantly localized in the nuclei of luminal cells, with 89% enrichment in benign ducts and low-grade cancer, and 78% enrichment in high-grade cancer .

This nuclear retention has been validated in prostate cancer cell lines (22Rv1 and MDA PCa 2b) using droplet digital polymerase chain reaction (ddPCR) on RNA isolated from nuclear and cytoplasmic fractions . The nuclear enrichment pattern was comparable to well-established nuclear-retained long non-coding RNAs like MALAT1, highlighting the unusual nature of this finding for a protein-coding mRNA .

This subcellular localization pattern might have significant implications for understanding ANO7 regulation and function, potentially involving:

• Post-transcriptional regulation mechanisms

• Nuclear retention as a regulatory mechanism controlling protein expression

• Possible non-canonical functions of the ANO7 transcript

These findings open new avenues for research into the regulatory mechanisms controlling ANO7 expression and function in normal and cancerous prostate tissue.

How does ANO7 correlate with other molecular markers in prostate cancer?

ANO7 expression shows significant correlations with several important molecular markers in prostate cancer:

• TMPRSS2:ERG fusion: Low ANO7 expression is significantly linked to the presence of TMPRSS2:ERG fusion (p<0.0001)

• Androgen receptor (AR): Low ANO7 expression correlates with elevated AR expression (p<0.0001)

• Chromosomal deletions: Low ANO7 expression is associated with 9 of 11 studied chromosomal deletions (p<0.05 for each)

• PTEN deletion: A particularly strong association exists between low ANO7 expression and PTEN deletion, suggesting a potential functional relationship with the PTEN/AKT pathway

These correlations provide insights into the potential biological mechanisms through which ANO7 might influence prostate cancer development and progression, integrating it into the broader landscape of prostate cancer molecular subtypes.

What are the critical factors for ANO7 antibody validation?

Proper validation of ANO7 antibodies is essential for reliable research outcomes. Key validation approaches include:

• Specificity testing:

  • Western blot detection of the expected 106 kDa band

  • Testing in positive control samples (e.g., HEK-293 cells expressing ANO7)

  • Comparison with negative controls

• Reproducibility assessment:

  • Consistent staining patterns across multiple experiments

  • Evaluation of lot-to-lot variations

• Correlation validation:

  • Comparing protein detection with mRNA expression

  • Studies have confirmed correlation between ANO7 mRNA and protein expression in prostate tissue using parallel sections for fluorescent in situ hybridization and immunohistochemistry

• Technical optimization:

  • Titration to determine optimal antibody concentration (typically 1:500-1:1000 for Western blot)

  • Optimization of antigen retrieval conditions

  • Testing of different detection systems

Researchers should document validation results thoroughly to ensure reproducibility and reliability in ANO7 studies.

What experimental controls are recommended for ANO7 expression studies?

To ensure robust and reproducible results when studying ANO7 expression, researchers should employ several key controls:

• Positive tissue controls:

  • Normal prostate tissue (known to express high levels of ANO7)

  • Well-characterized prostate cancer cell lines with known ANO7 expression

• Negative controls:

  • Non-prostate tissues (ANO7 expression is highly prostate-specific)

  • Antibody diluent without primary antibody to assess background staining

• Expression validation controls:

  • Correlation of protein detection with mRNA levels

  • Use of multiple antibodies targeting different epitopes when possible

• Quantification controls:

  • Standardized scoring systems with explicit criteria

  • Blinded assessment by multiple observers to reduce bias

  • Inclusion of internal reference standards for intensity calibration

These controls help mitigate technical variability and increase confidence in experimental findings related to ANO7 expression.

How might ANO7 serve as a therapeutic target in prostate cancer?

ANO7's prostate-specific expression pattern makes it a promising therapeutic target. Potential approaches include:

• Antibody-based therapeutics:

  • Development of antibody-drug conjugates targeting ANO7-expressing cells

  • Chimeric antigen receptor (CAR) T-cell therapy using ANO7 as a target

• Genetic therapy approaches:

  • Targeting ANO7 genetic variants (rs77559646, rs148609049) that are associated with aggressive disease

  • Developing splice-modulating therapies to alter ANO7 isoform expression

• Diagnostic applications:

  • Integration of ANO7 expression assessment in prognostic panels

  • Development of liquid biopsy approaches detecting ANO7 variants

The strong association between reduced ANO7 expression and poor prognosis (Cox hazard ratio of 2.98 for PSA recurrence in patients with negative vs. strong expression) highlights its potential value as both a biomarker and therapeutic target.

What are the methodological approaches to study ANO7 function?

Investigating ANO7 function requires multifaceted experimental approaches:

• Ion channel activity assessment:

  • Patch-clamp electrophysiology to measure chloride conductance

  • Calcium imaging to examine activation mechanisms

• Functional genomics:

  • CRISPR-Cas9 gene editing to create knockout or knock-in models

  • siRNA-mediated knockdown to assess acute loss of function

• Structure-function analysis:

  • Expression of ANO7 variants (including those associated with cancer) to assess functional alterations

  • Domain mapping to identify regions critical for channel activity and protein-protein interactions

• Integrated -omics approaches:

  • Transcriptomics following ANO7 manipulation to identify downstream pathways

  • Proteomics to identify ANO7 interaction partners

  • Phosphoproteomics to assess signaling pathway alterations

These methodological approaches will help elucidate ANO7's biological role and its contribution to prostate cancer pathogenesis.